GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Incannex Healthcare Inc (NAS:IXHL) » Definitions » Shiller PE Ratio

Incannex Healthcare (Incannex Healthcare) Shiller PE Ratio : (As of May. 28, 2024)


View and export this data going back to 2022. Start your Free Trial

What is Incannex Healthcare Shiller PE Ratio?

Shiller PE for Stocks: The True Measure of Stock Valuation


Incannex Healthcare Shiller PE Ratio Historical Data

The historical data trend for Incannex Healthcare's Shiller PE Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Incannex Healthcare Shiller PE Ratio Chart

Incannex Healthcare Annual Data
Trend Jun14 Jun15 Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23
Shiller PE Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Incannex Healthcare Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Shiller PE Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Incannex Healthcare's Shiller PE Ratio

For the Drug Manufacturers - Specialty & Generic subindustry, Incannex Healthcare's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Incannex Healthcare's Shiller PE Ratio Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Incannex Healthcare's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where Incannex Healthcare's Shiller PE Ratio falls into.



Incannex Healthcare Shiller PE Ratio Calculation

For Shiller PE Ratio, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller PE Ratio is also called PE10.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.

Incannex Healthcare's E10 for the quarter that ended in Mar. 2024 is calculated as:

For example, Incannex Healthcare's adjusted earnings per share data for the three months ended in Mar. 2024 was:

Adj_EPS=Earnings per Share (Diluted)/CPI of Mar. 2024 (Change)*Current CPI (Mar. 2024)
=-0.38/127.6062*127.6062
=-0.380

Current CPI (Mar. 2024) = 127.6062.

Incannex Healthcare Quarterly Data

Earnings per Share (Diluted) CPI Adj_EPS
201406 -0.090 98.352 -0.117
201409 0.000 98.816 0.000
201412 -0.002 99.002 -0.003
201503 0.000 99.187 0.000
201506 -0.009 99.838 -0.012
201509 0.000 100.302 0.000
201512 -0.001 100.673 -0.001
201603 0.000 100.488 0.000
201606 -0.001 100.859 -0.001
201609 0.000 101.602 0.000
201612 -0.898 102.159 -1.122
201703 0.000 102.624 0.000
201706 0.250 102.809 0.310
201709 0.000 103.460 0.000
201712 -0.026 104.110 -0.032
201803 0.000 104.574 0.000
201806 -0.026 104.945 -0.032
201809 0.000 105.410 0.000
201812 -0.015 105.967 -0.018
201903 0.000 105.967 0.000
201906 -0.010 106.617 -0.012
201909 0.000 107.174 0.000
201912 -0.014 107.917 -0.017
202003 0.000 108.289 0.000
202006 -0.014 106.246 -0.017
202009 0.000 107.917 0.000
202012 -0.017 108.846 -0.020
202103 0.000 109.496 0.000
202106 -4.623 110.332 -5.347
202109 0.000 111.168 0.000
202112 -0.019 112.654 -0.022
202203 0.000 115.069 0.000
202206 -4.981 117.112 -5.427
202209 0.000 119.248 0.000
202212 -0.050 121.477 -0.053
202303 -0.220 123.148 -0.228
202306 1.979 124.170 2.034
202309 0.000 125.656 0.000
202312 -0.330 126.399 -0.333
202403 -0.380 127.606 -0.380

Add all the adjusted EPS together and divide 10 will get our E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Incannex Healthcare  (NAS:IXHL) Shiller PE Ratio Explanation

Compared with the regular PE Ratio, which works poorly for cyclical businesses, the Shiller PE Ratio smoothed out the fluctuations of profit margins during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Shiller PE Ratio should give similar results to regular PE Ratio.

Compared with the PS Ratio, the Shiller PE Ratio makes the comparison between different industries more meaningful.


Be Aware

Shiller PE Ratio assumes that over the long term, businesses and profitability revert to their means. If a company's business model does not work in the future compared with the past, Shiller PE Ratio and PS Ratio will give false valuations.


Incannex Healthcare Shiller PE Ratio Related Terms

Thank you for viewing the detailed overview of Incannex Healthcare's Shiller PE Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Incannex Healthcare (Incannex Healthcare) Business Description

Traded in Other Exchanges
N/A
Address
8 Century Circuit Norwest, Suite 105, Sydney, NSW, AUS, 3000
Incannex Healthcare Inc is a clinical stage pharmaceutical company developing medical cannabis products for the treatment of Obstructive Sleep Apnea (OSA), Traumatic Brain Injury (TBI)/Concussion, Rheumatoid Arthritis, Inflammatory Bowel Disease, and Inflammatory Lung Conditions. The company has an Australian license to import, export, and distribute medicinal cannabis products and has launched a line of cannabinoid products.